About Therapixel
Therapixel is one of the leading French software companies specializing in artificial intelligence applied to medical imaging, founded in 2013 by Olivier Clatz (INRIA Sophia Antipolis – Méditerranée) and Pierre Fillard (INRIA Saclay Ile-de-France). The company's mission is to make innovative medical imaging technology accessible to all healthcare professionals by delivering pertinent information at the right time. Therapixel gained international recognition in 2017 by winning the DREAM Digital Mammography Challenge, a global competition involving nearly 1,200 research teams focused on developing algorithms for mammogram diagnostic assistance. The company processed 640,000 anonymous digital mammogram images from over 86,000 patients to develop its breakthrough technology. The company's flagship product, MammoScreen®, is an AI-powered software that assists radiologists in reading digital mammograms to detect and qualify suspicious tissue that may be cancerous. Using deep learning technologies trained on hundreds of thousands of cases annotated by breast radiologist experts and confirmed by biopsy, MammoScreen has demonstrated the ability to detect 42% of cancers one year prior to diagnosis and 38.5% two years prior. The technology reduces reader fatigue, improves consistency, and lowers unnecessary recalls, minimizing patient anxiety. Therapixel initially developed Fluid, a touchless medical imaging navigation system for operating rooms, which was sold to Videomed in June 2020 to allow the company to focus entirely on radiology. The company operates research teams in Paris and software development teams in Nice, France. MammoScreen is both FDA-cleared and CE-marked, and Therapixel complies with ISO 13485 standards. Recent partnerships include Mayo Clinic and Onsite Women's Health, expanding MammoScreen's deployment across major healthcare networks in the United States.
Mission & Story
Mission
The passion of people, the performance of technology and their complementarity can save lives
Founding Story
Founded in 2013 by Olivier Clatz from INRIA Sophia Antipolis – Méditerranée and Pierre Fillard from INRIA Saclay Ile-de-France. The company initially developed Fluid, a touchless medical imaging navigation system for operating rooms. The pivotal moment came in 2017 when Therapixel won the DREAM Digital Mammography Challenge, an international competition involving 1,200 research teams, processing 640,000 mammogram images from 86,000+ patients with limited computing resources (14 days in Amazon cloud).
Clinical Focus
Medical conditions and clinical areas addressed by Therapixel.
Who It Serves
Milestones & Awards
Recent Milestones
Mayo Clinic adoption (June 2025), Onsite Women's Health partnership for 150+ locations (April 2025), FDA clearance for 3D/Digital Breast Tomosynthesis (November 2021), €15M Series B financing (May 2022), new version with prior exam analysis (May 2022), prospective clinical study launch in France (October 2022)
Awards & Recognition
Winner of 2017 DREAM Digital Mammography Challenge (global competition with 1,200 research teams)
Key Partnerships
Social & Media
Latest Updates
Therapixel will be showcasing MammoScreen™ at the virtual ECR 2021
Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis
Therapixel receives the CE mark for its Artificial Intelligence-based software (AI) MammoScreen™
Scientific Publications
Therapixel and RAD-AID International Announce Breast Imaging AI Collaboration for Global Health
Company Details
- Founded
- 2013
- Headquarters
- Nice, Provence-Alpes-Côte d'Azur, France
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Similar Companies in this Market
View all 189 →
A2z Radiology Ai
AI platform that triages urgent abdomen-pelvis CT findings and prioritizes flagged studies in radiology worklists.
Adas3D Medical S.L
11-50 employees
Adas3D Medical develops medical imaging software that extracts key clinical information from cardiac MRI and CT scans for electrophysiologists. The software helps plan, guide, and monitor catheter ablation procedures by visualizing and quantifying fibrotic tissue in the heart.
AEYE Health
11-50 employees
AEYE Health provides FDA-cleared autonomous AI diagnostic screening for diabetic retinopathy and other eye diseases using retinal images. Their point-of-care solution enables primary care physicians to screen and diagnose patients instantly with portable or desktop cameras.
Agfa HealthCare N.V.
AGFA HealthCare provides enterprise imaging platforms that unify medical imaging across specialties. The company delivers PACS, vendor neutral archives, AI-powered workflow orchestration, and cloud-based imaging solutions to hospitals and healthcare systems worldwide.
AI4MedImaging Medical Solutions
AI4MedImaging provides AI-powered medical imaging solutions distributed through aycan Medical Systems in the Americas. Their flagship product, AI4CMR, is software as a medical device (SaMD) that automates the interpretation of cardiac magnetic resonance imaging using artificial intelligence.
Aidence
Aidence, now part of DeepHealth, develops AI-powered clinical applications for radiology and medical imaging. The company specializes in lung nodule detection, classification, and patient management solutions that empower radiologists and physicians in interpreting medical images.
Aidoc
growth · 350 employees
Aidoc empowers health systems to improve patient outcomes and operations with enterprise-grade healthcare AI.
Aikenist Technologies Pvt Ltd
21-100 employees
Aikenist Technologies is a MedTech company specializing in advanced AI-driven solutions for radiology imaging. Their offerings include an FDA-approved AI PACS and RIS with integrated viewer, appointment scheduling, billing modules, and AI tools for stroke, oncology, and neuro detection.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.